EUVIMEDEUVIMED entdecken
Crossref

The role of immune checkpoint inhibitors: Variable number of tandem repeat (VNTR) polymorphism in the second exon of the P‐selectin glycoprotein ligand‐1 ( PSGL‐1 ) gene polymorphism in multiple myeloma

Yasemin Oyaci, Mustafa Pehlivan, Sacide Pehlivan, Tahir Alper Cinli, Fatima Ceren Tuncel, Elif Ertas, Istemi Serin iD

Molecular Carcinogenesis · 2024

DOI: 10.1002/mc.23787 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Carcinogenesis, 2024. Verfasst von Yasemin Oyaci und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Graduate Studies in Health Sciences, Istanbul University, Istanbul, Turkey. Hauptthemen laut MEDLINE: Multiple Myeloma, Immune Checkpoint Inhibitors, Membrane Glycoproteins, Minisatellite Repeats. Die Arbeit nennt 31 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Somatic mutations and polymorphisms may play a role in multiple myeloma (MM) susceptibility and survival. One of the immune checkpoint inhibitors is P‐selectin glycoprotein ligand‐1 (PSGL‐1); the majority of tumor‐infiltrating leukocytes express PSGL‐1, causing T cell and immune inhibition via PSGL‐1 mediator molecules. We aimed to investigate the effect of variable number of tandem repeat (VNTR) polymorphism in the second exon of the PSGL‐1 gene on MM susceptibility, response to treatment and survival in our patient group. A total of 238 patients diagnosed with MM between January 2010 and January 2021 and 162 healthy individuals as a control group were included in this cross‐sectional study. The genotypes of the VNTR polymorphism in the second exon of the PSGL‐1 gene were statistically compared between patients and healthy controls; the statistically significant effects of the genotypes on response to first‐line treatment and survival were examined. The AC genotype was significantly higher in healthy controls compared to patients diagnosed with MM ( p < 0.001). The median PFS in patients with AA/AB/AC was 56 months, while it was 100 months in patients with BB/CC. The hazard ratio of 1.34 for PFS was found to be clinically significant and having the BB/CC genotype could provide a longer PFS compared to others, but it was not statistically significant due to the sample size. Our study results will shed light on new study plans in terms of immune checkpoint target therapies among conventional treatment preferences in MM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaImmune Checkpoint InhibitorsMembrane GlycoproteinsMinisatellite RepeatsHumansMaleFemaleMiddle AgedAgedPolymorphism, GeneticExonsCross-Sectional StudiesCase-Control StudiesAdultGenotypeGenetic Predisposition to DiseaseAged, 80 and overPrognosis

Stichwörter der Autor:innen

P‐selectin glycoprotein ligand‐1 (PSGL‐1)multiple myelomaprognosissurvivalsusceptibility

Substanzen

P-selectin ligand proteinImmune Checkpoint InhibitorsMembrane Glycoproteins

Autor:innen und Institutionen

  • Institute of Graduate Studies in Health Sciences, Istanbul University, Istanbul, Turkey.
  • Department of Hematology, Basaksehir Cam and Sakura City Hospital, Turkey.
  • Department of Medical Biology, Istanbul Faculty of Medicine, Istanbul University, Fatih, Turkey.
  • Department of Hematology, Istanbul Training and Research Hospital, University of Health Sciences, Istanbul, Turkey.
  • Department of Biostatistics, Selcuk University, Konya, Turkey.
  • Department of Hematology, Agri Training and Research Hospital, Ibrahim Cecen University, Agri, Turkey.

ORCID-Profile: Istemi Serin

Zitieren

APA

Oyaci, Y., Pehlivan, M., Pehlivan, S., Cinli, T. A., Tuncel, F. C., Ertas, E., & Serin, I. (2024). The role of immune checkpoint inhibitors: Variable number of tandem repeat (VNTR) polymorphism in the second exon of the P‐selectin glycoprotein ligand‐1 ( PSGL‐1 ) gene polymorphism in multiple myeloma. Molecular Carcinogenesis. https://doi.org/10.1002/mc.23787

Vancouver

Oyaci Y, Pehlivan M, Pehlivan S, Cinli TA, Tuncel FC, Ertas E, et al. The role of immune checkpoint inhibitors: Variable number of tandem repeat (VNTR) polymorphism in the second exon of the P‐selectin glycoprotein ligand‐1 ( PSGL‐1 ) gene polymorphism in multiple myeloma. Molecular Carcinogenesis. 2024. doi:10.1002/mc.23787

BibTeX
@article{Oyaci2024,
  author = {Oyaci, Yasemin and Pehlivan, Mustafa and Pehlivan, Sacide and Cinli, Tahir Alper and Tuncel, Fatima Ceren and Ertas, Elif and Serin, Istemi},
  title = {The role of immune checkpoint inhibitors: Variable number of tandem repeat (VNTR) polymorphism in the second exon of the P‐selectin glycoprotein ligand‐1 ( PSGL‐1 ) gene polymorphism in multiple myeloma},
  journal = {Molecular Carcinogenesis},
  year = {2024},
  doi = {10.1002/mc.23787}
}
Kostenlos starten →